UEGW 2024 Highlights Podcast

In this episode [13:25], Medicom’s correspondent covers 6 presentations from the annual United European Gastroenterology Week (UEGW 2024), held in Vienna, Austria from 12-15 October 2024.

The topics discussed are:

1. Cendakimab meets primary endpoints in eosinophilic oesophagitis
   Cendakimab outperformed placebo in patients with eosinophilic oesophagitis across various efficacy endpoints in a phase 3 study. These results were consistent in the sub-population of steroid-refractory patients.
2. TACITO: Does FMT improve ICI plus VEGFR TKI therapy in mRCC?
   Patients with metastatic renal cell carcinoma appeared to experience an additional benefit from targeted faecal microbiota transplantation on top of their regimen of pembrolizumab plus axitinib, in the phase 2 TACITO trial.
3. Tradipitant improves symptoms of motion sickness
   The investigational agent tradipitant successfully reduced the incidence of nausea and vomiting associated with motion sickness in a clinical trial. Both the low dose and the high dose were well-tolerated according to the authors.
4. Encouraging results for L-carnitine in non-alcoholic fatty liver disease
   L-carnitine was associated with improvements in markers of non-alcoholic fatty liver disease when this intervention was compared with lifestyle advice in a randomised clinical trial.
5. An accelerated treatment approach may save lives in pancreatic walled-off necrosis
   An accelerated treatment algorithm appeared to benefit patients with large pancreatic walled-off necrosis in terms of length-of-stay in the hospital and major complications compared with the standard endoscopic step-up approach, according to interim results of the ACCELERATE trial.
6. TL1A inhibitor tulisokibart shows potential in ulcerative colitis
   In the extension period of the phase 2 ARTEMIS-UC study, tulisokibart displayed durable improvements in clinical and endoscopic outcomes in patients with moderately to severely active ulcerative colitis. A phase 3 programme has been launched to assess this agent in a larger population of patients.

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers



Posted on 28 October 202428 October 2024